Cargando…

A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation

The scarcity of age-appropriate pharmaceutical formulations is one of the major challenges impeding successful management of tuberculosis (TB) prevalence in minors. To this end, we designed and assessed the quality of a multiparticulate reconstitutable suspension powder containing fixed dose rifampi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rampedi, Penelope N., Ogunrombi, Modupe O., Wesley-Smith, James, Adeleke, Oluwatoyin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861895/ https://www.ncbi.nlm.nih.gov/pubmed/36678693 http://dx.doi.org/10.3390/pharmaceutics15010064

Ejemplares similares

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Development and Evaluation of a Reconstitutable Dry Suspension Containing Isoniazid for Flexible Pediatric Dosing
por: Adeleke, Oluwatoyin A., et al.
Publicado: (2020)

Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery
por: Mehanna, Mohammed M, et al.
Publicado: (2019)

A case of thrombocytopenia caused by rifampicin and pyrazinamide
por: Bansal, Rekha, et al.
Publicado: (2013)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
por: Maphalle, Lehlogonolo N. F., et al.
Publicado: (2022)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
por: Nardotto, Glauco Henrique Balthazar, et al.
Publicado: (2021)

Multiparticulate System for Colon Targeted Delivery of Ondansetron
por: Jose, S., et al.
Publicado: (2010)

Acceptability of placebo multiparticulate formulations in children and adults
por: Lopez, Felipe L., et al.
Publicado: (2018)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Formulation and evaluation of multiparticulate system for chronotherapeutic delivery of salbutamol sulphate
por: Chaudhari, Pallavi M., et al.
Publicado: (2012)

Mucoadhesive Multiparticulate Drug Delivery Systems: An Extensive Review of Patents
por: Komati, Someshwar, et al.
Publicado: (2019)

Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases
por: Navarro-Ruíz, Eva, et al.
Publicado: (2022)

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
por: Brindle, Richard, et al.
Publicado: (2001)

Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis
por: Pouplin, Thomas, et al.
Publicado: (2016)

Theoretically Guided Analytical Method Development and Validation for the Estimation of Rifampicin in a Mixture of Isoniazid and Pyrazinamide by UV Spectrophotometer
por: Khan, Mohammad F., et al.
Publicado: (2017)

Development and in vitro Evaluation of Enteric Coated Multiparticulate System for Resistant Tuberculosis
por: Rahman, Md. A., et al.
Publicado: (2008)

Development of orally disintegrating tablets comprising controlled-release multiparticulate beads
por: Venkatesh, Gopi M., et al.
Publicado: (2012)

Damage of testicular cell macromolecules and reproductive capacity of male rats following co-administration of ethambutol, rifampicin, isoniazid and pyrazinamide
por: Shayakhmetova, Ganna Mykhailivna, et al.
Publicado: (2012)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
por: Imbeah, Emelia Priscilla, et al.
Publicado: (2022)

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
por: Sibley, Laura, et al.
Publicado: (2022)

A Case of Delusional Disorder With Abuse of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, the First-Line Anti-tuberculosis Therapy Drugs in India
por: Sathiyamoorthi, Sathiyanarayanan, et al.
Publicado: (2023)

Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance
por: Tirpude, Rakesh N., et al.
Publicado: (2011)

Impact of Surface Properties of Core Material on the Stability of Hot Melt-Coated Multiparticulate Systems
por: Schertel, Sonja, et al.
Publicado: (2021)

A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine
por: Amponsah, Seth Kwabena, et al.
Publicado: (2021)

Acceptability of Multiparticulate Dosing Using Sympfiny(®) Delivery System with Children (Age 1–12)
por: Abeln, Kate, et al.
Publicado: (2022)

Pyrazinamide induced thrombocytopenia
por: Kant, Surya, et al.
Publicado: (2010)

Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
por: Zhu, Hui, et al.
Publicado: (2015)

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2017)

Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice
por: Lai, Jacqueline Mui Lan, et al.
Publicado: (2019)

A Simple and Sensitive UPLC–UV Method for Simultaneous Determination of Isoniazid, Pyrazinamide, and Rifampicin in Human Plasma and Its Application in Therapeutic Drug Monitoring
por: Jiang, Zhimei, et al.
Publicado: (2022)

Efficiency of Multiparticulate Delivery Systems Loaded with Flufenamic Acid Designed for Burn Wound Healing Applications
por: Dinescu, Sorina, et al.
Publicado: (2019)

PYRAZINAMIDE-INDUCED MACULOPAPULAR RASH
por: Khayyam, Khalid Umer, et al.
Publicado: (2010)

A Novel Oral Syringe for Dosing and Administration of Multiparticulate Formulations: Acceptability Study in Preschool and School Children
por: Katarzyna Hofmanová, Justyna, et al.
Publicado: (2020)

Powder and Reconstituted Properties of Commercial Infant and Follow-On Formulas †
por: Murphy, Eoin G., et al.
Publicado: (2020)

Mechanism of Insoluble Aggregate Formation in a Reconstituted Solution of Spray-Dried Protein Powder
por: Tao, Yeqing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jg4uh0v37sp1jkcpsok58na1de